Human trials of the vaccine will expand to hundreds more people in the “coming weeks.” LONDON: A leading British scientist has said a Covid-19 vaccine could be rolled out across the country as early as the first half of next year. Professor Robin Shattock leads the team working on Imperial College London’s vaccine, one of the UK’s two most promising research programs. He told Sky News: “We anticipate if everything goes really well, that we"ll get an answer as to whether it works by early next year. “Assuming that the funding is there to purchase that vaccine, we could have that vaccine rolled out across the UK in the first half of next year.” Shattock also warned that there was “no certainty” that any of the vaccines currently being developed would work, but said the risk of that is “very, very low.” Imperial College London is now conducting human trials of their vaccine, with 15 volunteers having received it so far. Shattock said this will be ramped up in the “coming weeks” to include another 200 to 300 patients. “I think we"re very lucky in the UK that we have two very strong candidates, the one from Imperial, the one from Oxford, and so we’re pretty well placed, but there"s still not a certainty that either of those two will work,” he said. Oxford University is also developing a vaccination for Covid-19, in partnership with British-Swedish pharmaceutical giant AstraZeneca. While Shattock said he hopes Imperial College London’s vaccine will be available for the whole of the UK in the first half of next year, it is unclear how long it would take for it to be available outside of the country. The UK, European Union and the US have all invested huge sums into vaccine development, and struck deals with pharmaceutical companies worth hundreds of millions of dollars each to ensure first-in-line access to successful vaccinations. However, international organizations such as the UN, International Red Crescent and Red Cross, and Doctors Without Borders have raised concerns that the world’s poorest countries will be unable to access vaccinations and effective Covid-19 treatments due to rich countries outspending them.